1. Introduction
Raw milk is commonly produced intensively due to its collection from dispersed farms and subsequent transportation to processing plants for uniform treatment. Throughout the stages of collection, transportation, and waiting for processing, raw milk undergoes a significant duration (several hours), imposing heightened demands on its quality [
1,
2,
3]. Microorganisms play a pivotal role in influencing the quality of raw milk. Given its nutrient-rich composition, raw milk provides an optimal environment and nutrient matrix that facilitate rapid microbial reproduction [
4]. Consequently, this can result in undesirable outcomes, such as off-flavors, sourness, discoloration, and a loss of the characteristic freshness associated with milk [
1]. Additionally, microorganisms break down and consume essential nutrients present in milk, including fats, proteins and vitamins. This process may lead to a reduction in the nutrient content of raw milk, thereby impacting the nutritional value of the final dairy product [
5]. To ensure the provision of high-quality and safe dairy products while prioritizing consumer health and satisfaction, it is imperative to implement effective control measures aimed at mitigating or eliminating microbial hazards inherent in raw milk [
2,
4].
The sources of microorganisms in raw milk are much more varied; microorganisms can be present in the skin of the cow's udder and teats, and are passed on to the milk when skin microorganisms come into contact with the milk during the milking process [
4,
5]. In addition, the environment, insects and rodents, milking equipment, and collection devices are all potential sources of microorganisms in raw milk [
6]. Notably, these sources of microbial contamination highlight the need to inhibit microbial colonisation through effective technological means [
7]. Researchers have explored the use of high pressure to inactivate microorganisms in raw milk while preserving its nutritional quality. However, due to the complexity of high-pressure equipment and limited treatment efficiency, it is not suitable for large-scale implementation [
8]. Non-thermal plasma treatment offers an alternative approach to generating reactive oxygen and nitrogen species that can penetrate microorganisms and inhibit or kill them. However, these oxides can also cause oxidation of raw milk, leading to a decline in its quality as a complex emulsion system [
9]. Conventional sterilization methods may destabilize raw milk by affecting its composition and structure. To overcome these challenges, alternative technologies, such as gas conditioning or non-thermal treatments, are being investigated to minimize adverse effects on raw milk while preserving its nutritional value and sensory properties [
10].
CO
2 has been used for fresh milk storage and preservation because it does not affect the nutritional content or flavor compared to conventional heat treatments. Also, CO
2 is a natural compound that does not leave harmful residues in the product or the environment [
11,
12]. CO
2 has been used for food preservation. When CO
2 is dissolved in milk, it forms carbonic acid, which lowers the pH of the milk. Many bacteria, including those that cause spoilage, cannot survive or grow effectively in this more acidic environment [
13,
14]. In addition, by replacing oxygen with CO
2 in the storage container, packaging or food systems (a technique known as Modified Atmosphere Packaging), the growth of aerobic bacteria and fungi is inhibited. These microorganisms require oxygen to grow, thus removing or reducing oxygen levels can help extend the shelf life of raw milk [
15].
In view of the complexity of the raw milk system and microbial community succession, the metabolic pattern of CO2 treatment on raw milk and microorganisms was analyzed by using macro-genome and metabolome, and then the molecular mechanism by which CO2 prolongs the shelf life of raw milk was clarified. The results of the study provide a theoretical basis for the application of CO2 in raw milk.
4. Discussion
The diversity of microbial communities in raw milk is usually considered as one of the key factors affecting milk quality, because udder surfaces, milking instruments, containers and environment are potential sources of microorganisms, which leads to microorganisms being inevitable in raw milk [
18]. Milk being a nutrient rich liquid is rich in water, proteins, fats, lactose, etc. which makes it a good medium for microbial growth and multiplication [
19]. These microorganisms include bacteria, molds and yeasts, among others. Firstly, it was found that
Stenotrophomonas maltophilia,
Lactococcus lactis and
Chryseobacterium sp. NEB161 were the dominant strains of raw milk, with a high percentage of 81.7%. The cold storage process altered the microbial colony diversity of raw milk, and the dominant strains at 6 days were
Acinetobacter guillouiae,
Pseudomonas fluorescens,
Serratia liquefaciens,
Pseudomonas simiae and
Leuconostoc mesenteroides, with a percentage of 56.2%. These results also verified that the microbial community is a key factor in the spoilage of raw milk. Therefore, it is necessary to use appropriate techniques to inhibit the growth and multiplication of microorganisms in raw milk. Several researchers have shown that adding CO
2 to food reduced the rate of food spoilage and the growth of disease-causing microorganisms [
19]. We found that CO
2 treatment significantly inhibited the propagation of the dominant colonies
Acinetobacter guillouiae,
Pseudomonas fluorescens,
Serratia liquefaciens and
Pseudomonas simiae in the CO
2-treated group as compared with the control group. The percentage in the CO
2 treated group was only 0.2%. CO
2 treatment significantly improved the storage period of raw milk (
Figure 1), indicating that CO
2 improved the quality of raw milk by suppressing microbial levels and diversity.
Through microbiomics analysis, CO
2 was found to prolong the storage period of raw milk by inhibiting microbial reproduction, but the exact mechanism of its antimicrobial effect is still unclear [
12]. CO
2 is highly soluble in water and lipids, and can form carbonic acid in aqueous solutions, which can lead to changes in pH in the suspension medium, and a decrease in pH inhibits the growth and metabolism of certain microorganisms [
20]. CO
2 significantly lowered the pH of raw milk (
Figure 1). Another view is that oxygen is a necessary electron acceptor in the metabolism of aerobic bacteria and is a specific electron acceptor for parthenogenetic anaerobes. Supplementation of raw milk with CO
2 reduced the oxygen content of the system, which in turn inhibited bacterial metabolism and reduced growth rates [
21]. CO
2 treatment significantly inhibited the levels of
Acinetobacter guillouiae,
Pseudomonas fluorescens,
Serratia liquefaciens and
Pseudomonas simiae (
Figure 3), which inhibited Gram-negative aerobic bacteria, suggesting that CO
2 inhibited the growth and reproduction of aerobic microorganisms and prolonged the shelf life of raw milk by reducing the oxygen content of the system.
Microorganisms in raw milk systems can utilize the nutrients in milk for growth and reproduction while breaking down substances, such as proteins, fats and lactose. For example, the pH of milk decreases when lactose is broken down to lactic acid [
22,
23]. Proteins are broken down, producing toxic substances, such as indole, sulfur and fecal deodorant, as well as foul odors. To be precise, the growth and reproduction of microorganisms is the metabolic process, which leads to changes in the metabolites of the raw milk system through a variety of metabolic processes, reducing the stability of the raw milk system and even spoilage [
23,
24]. It is worth noting that microbial effects on metabolites are mainly metabolic, including pyrimidine metabolism, arginine and proline metabolism, phenylalanine metabolism, aminoacyl tRNA biosynthesis, glycine, serine and threonine metabolism, lysine degradation, pantothenate and coenzyme A biosynthesis, and pyruvate metabolism (
Table 1).
Pyrimidine metabolism refers to the process of pyrimidine nucleotide synthesis and degradation in the cell and is an important component of nucleic acid synthesis. Through pyrimidine metabolism, cells are able to synthesize and maintain sufficient levels of pyrimidine nucleotides to support DNA and RNA synthesis and the stability of genetic material [
25,
26]. Microbial reproduction requires replication of genetic material, and reduced levels of metabolites, such as cytidylic acid, orotate and uridine, inhibit microbial growth and reproduction (
Table S2). In addition, pyrimidine nucleotide degradation produces uracil, which in turn is converted to β-aminobutyric acid, which is involved in amino acid and energy metabolic pathways. The inhibition of energy production results from reduced levels of orotate [
27]. The accumulation of N-carbamoyl-L-aspartate, a key compound in the metabolism of alanine, aspartic acid and glutamic acid, suggested that the processes involved in the synthesis of amino acids and the metabolism of other nitrogen compounds were inhibited.
Arginine and proline metabolism can generate nitric oxide (NO) and polyamine compounds, which play important roles in physiological processes, such as cell signaling, immunomodulation and blood flow regulation [
28]. In addition, proline metabolism produces polyamines and cofactors required for post-translational modification of proteins, which play key roles in cell growth and development [
29]. Phenylalanine metabolism produces tyrosine, and other important bioactive substances, which play important roles in neurotransmitter, hormone and pigment synthesis. Glycine, serine, and threonine metabolism involves a variety of enzymes and intermediates that have multiple effects on metabolites. For example, glycine metabolism produces alanine, which is involved in glucose and fatty acid metabolic pathways. Serine metabolism produces tryptophan. Threonine metabolism produces threonine and methionine, the compounds that play important roles in methionine metabolism and thionine metabolism [
30]. Amino acid metabolic processes are attenuated, but accumulation of betaine occurs in the glycerophospholipid metabolic pathway of glycine, serine, and threonine metabolism, which may be due to enhanced upstream glycerophospholipid metabolic activity. Lysine degradation generates intermediates, such as malondialdehyde, acetaldehyde and aminobutyric acid, which can be further involved in oxidation that can alter the stability of the raw milk system [
31]. Reduction in glutarate and N6, N6, N6-trimethyl-L-lysine levels were found in the lysine degradation pathway. Generally speaking, it was found that CO
2 treatment significantly inhibited amino acid metabolism and reduced microbial biological activity and acid accumulation. In addition, metabolic processes, such as carbohydrate metabolism, lipid metabolism, cell growth and death, and energy metabolism were also inhibited. Overall, CO
2 treatment effectively reduced the metabolism of microorganisms and thus inhibited their growth and reproduction.
Figure 1.
(A) Total bacterial counts of raw milk stored at 4 °C. (B) Effect of 2000 ppm CO2 treatment on raw milk pH.
Figure 1.
(A) Total bacterial counts of raw milk stored at 4 °C. (B) Effect of 2000 ppm CO2 treatment on raw milk pH.
Figure 2.
Microbial diversity of raw milk from the control (A) and CO2-treated (D) groups. (A) Number of common and unique microbial taxa in raw milk from both groups. (B) Simpson's index to assess the alpha diversity (genus level) of microbial communities in the two groups. (C) Principal component analysis (PCA) to assess β-diversity (genus level). (D) Chao1 index to assess the α-diversity (genus level) of the two microbial communities.
Figure 2.
Microbial diversity of raw milk from the control (A) and CO2-treated (D) groups. (A) Number of common and unique microbial taxa in raw milk from both groups. (B) Simpson's index to assess the alpha diversity (genus level) of microbial communities in the two groups. (C) Principal component analysis (PCA) to assess β-diversity (genus level). (D) Chao1 index to assess the α-diversity (genus level) of the two microbial communities.
Figure 3.
Microbial community structure of raw milk from the control (A) and CO2 treated (D) groups. (A) Linear discriminant analysis effect size (LEfSe) species branching diagram. The taxonomic branching diagram shows the taxonomic hierarchy of the major taxonomic units in the sample community from phylum to species (from inner circle to outer circle, phylum, order, order, family, genus, and species), with node sizes corresponding to the average relative abundance of the taxonomic unit; hollow nodes represent taxonomic units with insignificant intergroup differences, while nodes of other colors indicate that these taxonomic units exhibit significant intergroup differences and are more abundant in the sample than in the group represented by the color. higher abundance in the sample. Letters identify the names of taxonomic units with significant intergroup differences. (B) Histogram of LEfSe. Vertical coordinates show taxonomic units with significant differences between groups, and horizontal coordinates visualize the logarithmic scores of LDA analysis for each taxonomic unit in a bar chart. Taxonomic units are sorted by the size of the score to characterize their specificity within the sample grouping. Longer lengths indicate more significant differences for that taxonomic unit, and the color of the bar indicates the sample subgroup with the highest abundance corresponding to that taxonomic unit. (C) Taxonomic analysis of bacteria at the genus level. Horizontal coordinates are arranged according to the sample name, each bar represents one sample and is color-coded to distinguish each taxonomic unit, vertical coordinates represent the relative abundance of each taxonomic unit, the longer the bar, the higher the relative abundance of that taxonomic unit in the corresponding sample.
Figure 3.
Microbial community structure of raw milk from the control (A) and CO2 treated (D) groups. (A) Linear discriminant analysis effect size (LEfSe) species branching diagram. The taxonomic branching diagram shows the taxonomic hierarchy of the major taxonomic units in the sample community from phylum to species (from inner circle to outer circle, phylum, order, order, family, genus, and species), with node sizes corresponding to the average relative abundance of the taxonomic unit; hollow nodes represent taxonomic units with insignificant intergroup differences, while nodes of other colors indicate that these taxonomic units exhibit significant intergroup differences and are more abundant in the sample than in the group represented by the color. higher abundance in the sample. Letters identify the names of taxonomic units with significant intergroup differences. (B) Histogram of LEfSe. Vertical coordinates show taxonomic units with significant differences between groups, and horizontal coordinates visualize the logarithmic scores of LDA analysis for each taxonomic unit in a bar chart. Taxonomic units are sorted by the size of the score to characterize their specificity within the sample grouping. Longer lengths indicate more significant differences for that taxonomic unit, and the color of the bar indicates the sample subgroup with the highest abundance corresponding to that taxonomic unit. (C) Taxonomic analysis of bacteria at the genus level. Horizontal coordinates are arranged according to the sample name, each bar represents one sample and is color-coded to distinguish each taxonomic unit, vertical coordinates represent the relative abundance of each taxonomic unit, the longer the bar, the higher the relative abundance of that taxonomic unit in the corresponding sample.
Figure 4.
(A) PCA score plots for raw milk metabolite and quality control (QC) sample datasets. (B) Correlation plot for QC samples.
Figure 4.
(A) PCA score plots for raw milk metabolite and quality control (QC) sample datasets. (B) Correlation plot for QC samples.
Figure 5.
(A) OPLS-DA of the metabolite dataset of the control group. (B) OPLS-DA of the metabolite dataset of the CO2-treated group. (C) Alignment test results of the OPLS-DA of the control group. (D) Alignment test results of OPLS-DA for the CO2-treated group.
Figure 5.
(A) OPLS-DA of the metabolite dataset of the control group. (B) OPLS-DA of the metabolite dataset of the CO2-treated group. (C) Alignment test results of the OPLS-DA of the control group. (D) Alignment test results of OPLS-DA for the CO2-treated group.
Figure 6.
(A) Heatmap of DMs in the control group. (B) Heat map of DMs in the CO2-treated group. (C) Classification loop diagram (Ontology) of DMs in the control group. (D) Classification loop diagram (Ontology) of DMs in the CO2-treated group.
Figure 6.
(A) Heatmap of DMs in the control group. (B) Heat map of DMs in the CO2-treated group. (C) Classification loop diagram (Ontology) of DMs in the control group. (D) Classification loop diagram (Ontology) of DMs in the CO2-treated group.
Figure 7.
(A) Histogram of the distribution of microbiomics and metabolomics correlation coefficients (r) in the control group. (B) Histogram of the distribution of microbiomics and metabolomics correlation coefficients (r) in the CO2-treated group. The horizontal coordinate is the distribution of r between the two histologies, and the vertical coordinate is the density of the distribution of the corresponding r. r ≥ 0.7 or ≤ -0.7 indicates that the correlation is very strong, i.e., the blue negative correlation and the yellow positive correlation part of the plot. (C) Hierarchical clustering heat map of microbial and metabolite correlations in the control group (Top 28). (D) Hierarchical clustering heatmap of microbial and metabolite correlations in the CO2-treated group. Rows indicate metabolites and columns indicate genera. *** denotes correlation test P <0.001, ** denotes correlation test P <0.01, * denotes correlation test P <0.05.
Figure 7.
(A) Histogram of the distribution of microbiomics and metabolomics correlation coefficients (r) in the control group. (B) Histogram of the distribution of microbiomics and metabolomics correlation coefficients (r) in the CO2-treated group. The horizontal coordinate is the distribution of r between the two histologies, and the vertical coordinate is the density of the distribution of the corresponding r. r ≥ 0.7 or ≤ -0.7 indicates that the correlation is very strong, i.e., the blue negative correlation and the yellow positive correlation part of the plot. (C) Hierarchical clustering heat map of microbial and metabolite correlations in the control group (Top 28). (D) Hierarchical clustering heatmap of microbial and metabolite correlations in the CO2-treated group. Rows indicate metabolites and columns indicate genera. *** denotes correlation test P <0.001, ** denotes correlation test P <0.01, * denotes correlation test P <0.05.
Figure 8.
Microbiomics and untargeted metabolomics KEGG enrichment pathway analysis. (A) Microbiomics and identification of KEGG secondary metabolic pathway composition bar graphs for each sample. The vertical coordinates represent the relative abundance of each functional taxon; the longer the bar, the higher the relative abundance of that functional taxon in the corresponding sample. (B) Comparison group A-6d and D-6d KEGG pathway category bar graphs. G is Genetic Information Processing, M is Metabolism,E is Environmental Information Processing,o is Organismal Systems,H is Human Diseases. (C) Interaction maps of KEGG-enriched pathway-regulated metabolite networks shared by microbiomics and non-targeted metabolomics.
Figure 8.
Microbiomics and untargeted metabolomics KEGG enrichment pathway analysis. (A) Microbiomics and identification of KEGG secondary metabolic pathway composition bar graphs for each sample. The vertical coordinates represent the relative abundance of each functional taxon; the longer the bar, the higher the relative abundance of that functional taxon in the corresponding sample. (B) Comparison group A-6d and D-6d KEGG pathway category bar graphs. G is Genetic Information Processing, M is Metabolism,E is Environmental Information Processing,o is Organismal Systems,H is Human Diseases. (C) Interaction maps of KEGG-enriched pathway-regulated metabolite networks shared by microbiomics and non-targeted metabolomics.
Table 1.
Macrogenomics screened proteins corresponding to KO abundance and metabolomics annotated KEGG shared pathway analysis.
Table 1.
Macrogenomics screened proteins corresponding to KO abundance and metabolomics annotated KEGG shared pathway analysis.
No. |
ID |
ID |
Description |
Count |
KEGG ID |
Top Class |
1 |
ko02010 |
bta02010 |
ABC transporters |
10 |
C00719/C00062/C00025/C00120/C00093/C00299/C00475/C00881/C00079/C01181 |
Metabolism |
2 |
ko00240 |
bta00240 |
Pyrimidine metabolism |
9 |
C00055/C00380/C00299/C00475/C00881/C00106/C00438/C02067/C00295 |
Environmental Information Processing |
3 |
ko00330 |
bta00330 |
Arginine and proline metabolism |
7 |
C00062/C00581/C02305/C00025/C04281/C00022/C00300 |
Metabolism |
4 |
ko00360 |
bta00360 |
Phenylalanine metabolism |
5 |
C00082/C01586/C00805/C00079/C00022 |
Metabolism |
5 |
ko00770 |
bta00770 |
Pantothenate and CoA biosynthesis |
4 |
C00864/C00522/C00106/C00022 |
Metabolism |
6 |
ko00620 |
bta00620 |
Pyruvate metabolism |
4 |
C02504/C00074/C00149/C00022 |
Metabolism |
7 |
ko00260 |
bta00260 |
Glycine, serine and threonine metabolism |
4 |
C00719/C00581/C00022/C00300 |
Organismal Systems |
8 |
ko00310 |
bta00310 |
Lysine degradation |
4 |
C03793/C00489/C01181/C05548 |
Metabolism |
9 |
ko00970 |
bta00970 |
Aminoacyl-tRNA biosynthesis |
4 |
C00062/C00025/C00082/C00079 |
Human Diseases |
10 |
ko04141 |
bta04964 |
Proximal tubule bicarbonate reclamation |
3 |
C00074/C00025/C00149 |
Metabolism |
11 |
ko00020 |
bta00020 |
Citrate cycle (TCA cycle) |
3 |
C00074/C00149/C00022 |
Metabolism |
12 |
ko04922 |
bta04922 |
Glucagon signaling pathway |
3 |
C00074/C00149/C00022 |
Organismal Systems |
13 |
ko00250 |
bta00250 |
Alanine, aspartate and glutamate metabolism |
3 |
C00025/C00438/C00022 |
Genetic Information Processing |
14 |
ko05204 |
bta05207 |
Chemical carcinogenesis - receptor activation |
3 |
C14240/C03690/C00410 |
Metabolism |
15 |
ko00010 |
bta00010 |
Glycolysis / Gluconeogenesis |
3 |
C00074/C00221/C00022 |
Human Diseases |
16 |
ko00400 |
bta00400 |
Phenylalanine, tyrosine and tryptophan biosynthesis |
3 |
C00074/C00082/C00079 |
Human Diseases |
17 |
ko00030 |
bta00030 |
Pentose phosphate pathway |
3 |
C00257/C00221/C00022 |
Metabolism |
18 |
ko00564 |
bta00564 |
Glycerophospholipid metabolism |
3 |
C00588/C00093/C04230 |
Metabolism |
19 |
ko00630 |
bta00630 |
Glyoxylate and dicarboxylate metabolism |
3 |
C00025/C00149/C00022 |
Metabolism |
20 |
ko00380 |
bta00380 |
Tryptophan metabolism |
3 |
C01717/C05834/C00328 |
Human Diseases |
21 |
ko00230 |
bta00230 |
Purine metabolism |
3 |
C00366/C01444/C05513 |
Metabolism |
22 |
ko00460 |
bta05030 |
Cocaine addiction |
2 |
C00025/C00082 |
Metabolism |
23 |
ko05034 |
bta05034 |
Alcoholism |
2 |
C00025/C00082 |
Metabolism |
24 |
ko05014 |
bta05014 |
Amyotrophic lateral sclerosis |
2 |
C00062/C00025 |
Environmental Information Processing |
25 |
ko00220 |
bta00220 |
Arginine biosynthesis |
2 |
C00062/C00025 |
Cellular Processes |
26 |
ko00290 |
bta00290 |
Valine, leucine and isoleucine biosynthesis |
2 |
C02504/C00022 |
Organismal Systems |
27 |
ko00780 |
bta00780 |
Biotin metabolism |
2 |
C00120/C01909 |
Metabolism |
28 |
ko04216 |
bta04216 |
Ferroptosis |
2 |
C00025/C00418 |
Metabolism |
29 |
ko05200 |
bta05200 |
Pathways in cancer |
2 |
C00410/C00149 |
Cellular Processes |
30 |
ko00730 |
bta00730 |
Thiamine metabolism |
2 |
C00082/C00022 |
Environmental Information Processing |
31 |
ko00410 |
bta00410 |
beta-Alanine metabolism |
2 |
C00864/C00106 |
Human Diseases |
32 |
ko00650 |
bta00650 |
Butanoate metabolism |
2 |
C00025/C00022 |
Metabolism |
33 |
ko00760 |
bta00760 |
Nicotinate and nicotinamide metabolism |
2 |
C01020/C00022 |
Metabolism |
34 |
ko00350 |
bta00350 |
Tyrosine metabolism |
2 |
C00082/C00022 |
Human Diseases |
35 |
ko00520 |
bta00520 |
Amino sugar and nucleotide sugar metabolism |
2 |
C00270/C00446 |
Human Diseases |
36 |
ko00860 |
bta00860 |
Porphyrin and chlorophyll metabolism |
2 |
C00025/C02800 |
Human Diseases |
37 |
ko04150 |
bta04150 |
mTOR signaling pathway |
1 |
C00062 |
Metabolism |
38 |
ko04114 |
bta04114 |
Oocyte meiosis |
1 |
C00410 |
Metabolism |
39 |
ko04914 |
bta04914 |
Progesterone-mediated oocyte maturation |
1 |
C00410 |
Metabolism |
40 |
ko04068 |
bta04068 |
FoxO signaling pathway |
1 |
C00025 |
Human Diseases |
41 |
ko05142 |
bta05142 |
Chagas disease |
1 |
C00062 |
Metabolism |
42 |
ko05016 |
bta05016 |
Huntington disease |
1 |
C00025 |
Organismal Systems |
43 |
ko05143 |
bta05143 |
African trypanosomiasis |
1 |
C00328 |
Metabolism |
44 |
ko00472 |
bta00472 |
D-Arginine and D-ornithine metabolism |
1 |
C00062 |
Environmental Information Processing |
45 |
ko05215 |
bta05215 |
Prostate cancer |
1 |
C00410 |
Metabolism |
46 |
ko04721 |
bta04721 |
Synaptic vesicle cycle |
1 |
C00025 |
Environmental Information Processing |
47 |
ko04066 |
bta04066 |
HIF-1 signaling pathway |
1 |
C00022 |
Metabolism |
48 |
ko00910 |
bta00910 |
Nitrogen metabolism |
1 |
C00025 |
Human Diseases |
49 |
ko04152 |
bta04152 |
AMPK signaling pathway |
1 |
C00022 |
Metabolism |
50 |
ko05012 |
bta05012 |
Parkinson disease |
1 |
C00082 |
Metabolism |
51 |
ko00480 |
bta00480 |
Glutathione metabolism |
1 |
C00025 |
Metabolism |
52 |
ko00561 |
bta00561 |
Glycerolipid metabolism |
1 |
C00093 |
Metabolism |
53 |
ko00640 |
bta00640 |
Propanoate metabolism |
1 |
C05984 |
Metabolism |
54 |
ko00052 |
bta00052 |
Galactose metabolism |
1 |
C00446 |
Metabolism |
55 |
ko00340 |
bta00340 |
Histidine metabolism |
1 |
C00025 |
Metabolism |
56 |
ko00071 |
bta00071 |
Fatty acid degradation |
1 |
C00489 |
Environmental Information Processing |
57 |
ko00524 |
bta04080 |
Neuroactive ligand-receptor interaction |
1 |
C00025 |
Metabolism |
58 |
ko00061 |
bta00061 |
Fatty acid biosynthesis |
1 |
C08362 |
Metabolism |
59 |
ko00040 |
bta00040 |
Pentose and glucuronate interconversions |
1 |
C00022 |
Metabolism |
60 |
ko00270 |
bta00270 |
Cysteine and methionine metabolism |
1 |
C00022 |
Metabolism |
61 |
ko00130 |
bta00130 |
Ubiquinone and other terpenoid-quinone biosynthesis |
1 |
C00082 |
Metabolism |